Comparison · NCT05267600-5a1ff994
Efgartigimod PH20 SC vs Placebo PH20 SC: Number of Participants With CDA Who Remained Free of Relapse Through Week 36
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Efgartigimod PH20 SC vs Placebo PH20 SC: Number of Participants With CDA Who Remained Free of Relapse Through Week 36. Trial comparisons, record NCT05267600-5a1ff994. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05267600-5a1ff994
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.14 | 0.0695 | 0.262 | wilson | |
| Risk in group 2 | 0.167 | 0.087 | 0.296 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0267 | -0.174 | 0.119 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.84 | 0.33 | 2.14 | log | |
| Odds ratio, group 1 over group 2 | 0.814 | 0.27 | 2.45 | log | |
| Number needed to treat, for one fewer participant with the outcome on Efgartigimod PH20 SC than on Placebo PH20 SC | 37.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Efgartigimod PH20 SC | All participants from Part A and Part B receiving efgartigimod PH20 SC. Participants received concurrent oral prednisone (or equivalent) at a starting dose of 0.5 mg/kg/day. The dose of prednisone was adjusted according to recommendations as per protocol. | 7 | 50 | OG000 |
| Group 2 | Placebo PH20 SC | All participants from Part A and Part B receiving placebo PH20 SC. Participants received concurrent oral prednisone (or equivalent) at a starting dose of 0.5 mg/kg/day. The dose of prednisone was adjusted according to recommendations as per protocol. | 8 | 48 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With CDA Who Remained Free of Relapse Through Week 36
- Description
Control of disease activity (CDA) is defined as the point at which new lesions ceased to form, established lesions began to heal, and pruritic symptoms started to abate. Relapse is defined as the appearance of 3 or more new lesions a month or at least 1 large lesion that did not heal within 1 week, or extension of established lesions or daily pruritus in a participant who had achieved CDA.
- Time frame
- up to week 36
- Population
Source ClinicalTrials.gov
Trial
- Title
- A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
- NCT number
- NCT05267600
- Phases
- PHASE2, PHASE3
- Conditions
- Bullous Pemphigoid
- Interventions
- efgartigimod PH20 SC, placebo, Prednisone
- Lead sponsor
- argenx
- Results first posted
- 2025-10-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05267600?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05267600-5a1ff994